References
- Soman B, Dias MC, Rizvi SA, Kardos A. Myasthenia gravis, myositis and myocarditis: A fatal triad of immune-related adverse effect of immune checkpoint inhibitor treatment. BMJ Case Reports. 2022 Dec;15(12). doi:10.1136/bcr-2022-251966
- Giovannini E, Bonasoni MP, D’Aleo M, Tamagnini I, Tudini M, Fais P, et al. Pembrolizumab-induced fatal myasthenia, myocarditis, and myositis in a patient with metastatic melanoma: Autopsy, histological, and immunohistochemical findings—A case report and literature review. International Journal of Molecular Sciences. 2023 Jun 30;24(13):10919. doi:10.3390/ijms241310919
- Leaver PJ, Jang HS-I, Vernon ST, Fernando SL. Immune checkpoint inhibitor-mediated myasthenia gravis with focal subclinical myocarditis progressing to symptomatic cardiac disease. BMJ Case Reports. 2020 May;13(5). doi:10.1136/bcr-2019-232920
- Paik JJ, Corse AM, Mammen AL. The coexistence of myasthenia gravis in patients with myositis: A case series. Seminars in Arthritis and Rheumatism. 2014 Jun;43(6):792–6. doi:10.1016/j.semarthrit.2013.12.005
- Yan J. Treatment-related adverse events of immune checkpoint inhibitors in clinical trials: A systematic review and meta-analysis. 2023 Aug 29; doi:10.37766/inplasy2023.8.0119
- Immune related-adverse events in patients receiving immune checkpoint inhibitors. Case Medical Research. 2020 Feb 13; doi:10.31525/ct1-nct04268368
- Saishu Y, Yoshida T, Seino Y, Nomura T. Nivolumab-related myasthenia gravis with myositis requiring prolonged mechanical ventilation: A case report. Journal of Medical Case Reports. 2022 Feb 14;16(1). doi:10.1186/s13256-022-03286
- Moreira A, Loquai C, Pföhler C, Kähler KC, Knauss S, Heppt MV, et al. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. European Journal of Cancer. 2019 Jan;106:12–23. doi:10.1016/j.ejca.2018.09.033
- Bawek SJ, Ton R, McGovern-Poore M, Khoncarly B, Narvel R. Nivolumab-induced myasthenia gravis concomitant with myocarditis, myositis, and hepatitis. Cureus. 2021 Sept 17; doi:10.7759/cureus.18040
- Schwab A, Assaad M, Hamadi R, Zurndorfer J, Abi Melhem R, Holtzbach J, et al. Pembrolizumab-induced myasthenia gravis and myositis: Literature review on neurological toxicities of programmed death protein 1 inhibitors. Journal of Medical Cases. 2022 Nov;13(11):530–5. doi:10.14740/jmc4008
- Morgado M, Plácido A, Morgado S, Roque F. Management of the adverse effects of immune checkpoint inhibitors. Vaccines. 2020 Oct 1;8(4):575. doi:10.3390/vaccines8040575
- Zubair AS, Roy B, Baehring JM, Nowak RJ. Myasthenia gravis in the setting of immune checkpoint inhibitor therapy: Practical considerations and opinion-based approach to acute management. Cureus. 2022 Oct 24; doi:10.7759/cureus.30638